ABVC - Company ID 0001173313
The table below shows ABVC BIOPHARMA, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $795.95K | - | - | $389.28K | $117.14K |
| Cost of revenue | - | - | - | - | $296.00 | $190.00 |
| Gross profit | - | $795.95K | - | - | $388.98K | $116.95K |
| R&D | $33.10K | $29.89K | $33.28K | $28.86K | $37.83K | $40.40K |
ABVC BIOPHARMA, INC. reported annual revenue of $296.00K for fiscal year 2025. That is down 41.9% from $509.59K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $752.00K |
| $798.25K |
| $690.09K |
| $615.37K |
| $557.60K |
| $653.78K |
| Operating income | -$1.57M | -$1.96M | -$2.29M | -$693.00K | -$302.32K | -$860.11K |
| Income tax | - | $527.00 | $23.63K | - | $355.00 | -$110.89K |
| Net income | -$1.56M | -$2.04M | -$2.26M | -$842.08K | -$394.77K | -$942.34K |
| EPS (diluted) | -$0.06 | -$0.09 | -$0.13 | -$0.06 | -$0.03 | -$0.08 |